Mark Agulnik

Summary

Affiliation: Northwestern University
Country: USA

Publications

  1. ncbi request reprint Malignancies of the head and neck: the role for molecular targeted agents
    Mark Agulnik
    Northwestern University, Feinberg School of Medicine, Division of Hematology Oncology, 676 North St Clair Street, Suite 850, Chicago, IL 60611, USA
    Expert Opin Ther Targets 11:207-17. 2007
  2. ncbi request reprint Head and neck cancer: changing epidemiology and public health implications
    Leslie Kim
    Division of Hematology Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
    Oncology (Williston Park) 24:915-9, 924. 2010
  3. doi request reprint A phase II study of tivozanib in patients with metastatic and nonresectable soft-tissue sarcomas
    M Agulnik
    Division of Hematology Oncology, Northwestern University, Feinberg School of Medicine, Chicago
    Ann Oncol . 2016
  4. doi request reprint An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas
    M Agulnik
    Division of Hematology Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago 60611, USA
    Ann Oncol 24:257-63. 2013
  5. pmc New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN)
    Mark Agulnik
    Department of Medicine, Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, 676 North Saint Clair Street, Suite 850, Chicago, IL 60611 2942, USA
    Med Oncol 29:2481-91. 2012
  6. pmc New developments in mammalian target of rapamycin inhibitors for the treatment of sarcoma
    Mark Agulnik
    Division of Medical Hematology Oncology, Northwestern University, Chicago, Illinois, USA
    Cancer 118:1486-97. 2012
  7. ncbi request reprint Nasopharyngeal carcinoma: current management, future directions and dental implications
    Mark Agulnik
    Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, 676 North Saint Clair Street, Chicago, IL 60611, USA
    Oral Oncol 44:617-27. 2008
  8. doi request reprint Neoadjuvant use of sunitinib in locally advanced GIST with intolerance to imatinib
    Jana Svetlichnaya
    Division of Hematology Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611 6189, USA
    Chemotherapy 58:30-3. 2012
  9. ncbi request reprint Promising newer molecular-targeted therapies in head and neck cancer
    Lili X Wang
    Division of Hematology Oncology, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA
    Drugs 68:1609-19. 2008
  10. ncbi request reprint The role of inhibitors of the epidermal growth factor in management of head and neck cancer
    Bruce Brockstein
    Department of Medicine, Northwestern University, Feinberg School of Medicine, Evanston, Illinois
    J Natl Compr Canc Netw 6:696-706. 2008

Collaborators

Detail Information

Publications29

  1. ncbi request reprint Malignancies of the head and neck: the role for molecular targeted agents
    Mark Agulnik
    Northwestern University, Feinberg School of Medicine, Division of Hematology Oncology, 676 North St Clair Street, Suite 850, Chicago, IL 60611, USA
    Expert Opin Ther Targets 11:207-17. 2007
    ....
  2. ncbi request reprint Head and neck cancer: changing epidemiology and public health implications
    Leslie Kim
    Division of Hematology Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
    Oncology (Williston Park) 24:915-9, 924. 2010
    ..Given that the majority of HNSCCs are the result of exposure to preventable public health risks, more focus should be given to this area...
  3. doi request reprint A phase II study of tivozanib in patients with metastatic and nonresectable soft-tissue sarcomas
    M Agulnik
    Division of Hematology Oncology, Northwestern University, Feinberg School of Medicine, Chicago
    Ann Oncol . 2016
    ..The primary endpoint of this study was progression free survival (PFS) rate at 16 weeks. Secondary end points were overall survival (OS), response rate, safety and correlative studies...
  4. doi request reprint An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas
    M Agulnik
    Division of Hematology Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago 60611, USA
    Ann Oncol 24:257-63. 2013
    ..To determine efficacy and safety of bevacizumab, a recombinant humanized antibody against vascular endothelial growth factor (VEGF), in the treatment of metastatic or locally advanced angiosarcoma and epithelioid hemangioendotheliomas...
  5. pmc New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN)
    Mark Agulnik
    Department of Medicine, Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, 676 North Saint Clair Street, Suite 850, Chicago, IL 60611 2942, USA
    Med Oncol 29:2481-91. 2012
    ..Ongoing large clinical trials are evaluating these emerging agents and combinations for the treatment of SCCHN...
  6. pmc New developments in mammalian target of rapamycin inhibitors for the treatment of sarcoma
    Mark Agulnik
    Division of Medical Hematology Oncology, Northwestern University, Chicago, Illinois, USA
    Cancer 118:1486-97. 2012
    ..The evidence from both preclinical and clinical studies supports further study of mTOR-targeting rapalogs in the treatment of various subtypes of sarcoma...
  7. ncbi request reprint Nasopharyngeal carcinoma: current management, future directions and dental implications
    Mark Agulnik
    Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, 676 North Saint Clair Street, Chicago, IL 60611, USA
    Oral Oncol 44:617-27. 2008
    ..Treatment innovations with molecularly targeted therapies and immunotherapy are being assessed to improve treatment outcomes in NPC and will impact oral complications and oral care...
  8. doi request reprint Neoadjuvant use of sunitinib in locally advanced GIST with intolerance to imatinib
    Jana Svetlichnaya
    Division of Hematology Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611 6189, USA
    Chemotherapy 58:30-3. 2012
    ..Here we present the case of a patient with locally advanced primary GIST who developed severe toxicity on imatinib therapy and was successfully treated with sunitinib in the neoadjuvant setting to achieve complete surgical resection...
  9. ncbi request reprint Promising newer molecular-targeted therapies in head and neck cancer
    Lili X Wang
    Division of Hematology Oncology, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA
    Drugs 68:1609-19. 2008
    ....
  10. ncbi request reprint The role of inhibitors of the epidermal growth factor in management of head and neck cancer
    Bruce Brockstein
    Department of Medicine, Northwestern University, Feinberg School of Medicine, Evanston, Illinois
    J Natl Compr Canc Netw 6:696-706. 2008
    ..Molecular and clinical markers of response and outcome are also discussed...
  11. doi request reprint Examination of national lymph node evaluation practices for adult extremity soft tissue sarcoma
    Karen L Sherman
    Northwestern Institute for Comparative Effectiveness Research NICER in Oncology, Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois Department of Surgery, Surgical Oncology and Quality Improvement Center, Northwestern University, Feinberg School of Medicine, Chicago, Illinois
    J Surg Oncol 110:682-8. 2014
    ..Our objectives were (1) to assess rates and predictors of nodal evaluation, and (2) to assess rates and predictors of nodal metastases...
  12. pmc Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial
    Gary K Schwartz
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Lancet Oncol 14:371-82. 2013
    ....
  13. doi request reprint Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis : results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at
    Narissa J Nonzee
    Robert H Lurie Comprehensive Cancer Center and Division of Hematology Oncology, Northwestern University, Chicago, Illinois 60611, USA
    Cancer 113:1446-52. 2008
    ..Few studies have examined the costs of supportive care for radiochemotherapy-induced mucosits/pharyngitis among patients with head and neck cancer (HNC) or lung cancers despite the documented negative clinical impact of these complications...
  14. doi request reprint Treatment of multiple keratoacanthomas with erlotinib
    David C Reid
    Department of Dermatology, Feinberg School of Medicine, Northwestern University, 676 N St Clair St, Suite 1600, Chicago, IL 60611, USA
    Int J Clin Oncol 15:413-5. 2010
    ..This is the first report of multiple keratoacanthomas responding to therapy with an EGFR tyrosine kinase inhibitor, and it supports an emerging role for the use of EGFR inhibitors in the management of cutaneous malignancies...
  15. doi request reprint Assessment of multimodality therapy use for extremity sarcoma in the United States
    Karen L Sherman
    Northwestern Institute for Comparative Effectiveness Research NICER in Oncology, Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois Surgical Outcomes and Quality Improvement Center, Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
    J Surg Oncol 109:395-404. 2014
    ..Our objectives were to examine multimodality treatment trends, practice patterns, and factors associated with neoadjuvant or postoperative adjuvant therapy utilization...
  16. doi request reprint Effect of recombinant human deoxyribonuclease on oropharyngeal secretions in patients with head-and-neck cancers treated with radiochemotherapy
    Bharat B Mittal
    Department of Radiation Oncology, Northwestern University, Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois, USA
    Int J Radiat Oncol Biol Phys 87:282-9. 2013
    ....
  17. ncbi request reprint New therapeutic options in gastrointestinal stromal tumors
    Eytan Stein
    Department of Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA
    Oncology (Williston Park) 22:206-11; discussion 215-6, 219. 2008
    ..With additional evaluation of other tyrosine kinase inhibitors and novel therapies against other molecular markers, the treatment paradigm for this malignancy should continue to evolve...
  18. doi request reprint Promising new molecular targeted therapies in head and neck cancer
    Kelly Dorsey
    Robert H Lurie Comprehensive Cancer Center and Division of Hematology Oncology, Northwestern University, 676 N St Clair, Suite 850, Chicago, IL 60611, USA
    Drugs 73:315-25. 2013
    ..On-going clinical trials are evaluating these emerging agents and their combinations in the treatment of SCCHN...
  19. doi request reprint Targeted therapies in bone sarcomas: current approach and future directions
    Jessica Lee Yarber
    Northwestern Memorial Hospital, Internal Medicine, Chicago, IL 60611, USA
    Expert Opin Investig Drugs 20:973-9. 2011
    ..Bone sarcomas are rare malignancies and once advanced, there is limited response to current chemotherapeutic regimens. Targeted therapies could have substantial impact on these diseases...
  20. ncbi request reprint Molecularly targeted therapies in adult soft tissue sarcomas: present approach and future directions
    Olivia Aranha
    Northwestern University, Robert H Lurie Comprehensive Cancer Center, Division of Hematology Oncology, Chicago, Illinois 60611, USA
    Expert Opin Ther Targets 12:197-207. 2008
    ..Sarcomas are rare neoplasms. Given the overwhelming chemotherapy resistance of the disease, patients with progressive and metastatic soft tissue sarcomas are ideal candidates for trials of investigational new drugs...
  21. doi request reprint Salivary gland malignancies: the role for chemotherapy and molecular targeted agents
    Sujani G Surakanti
    Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
    Semin Oncol 35:309-19. 2008
    ..Salivary gland-focused cooperative groups are necessary in order to accrue patients to these clinical trials and establish new treatment guidelines for these patients...
  22. pmc Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials
    Ricardo Costa
    Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
    Oncotarget . 2016
    ..This meta-analysis of randomized clinical trials aims to summarize current knowledge regarding the toxicity profile of these agents...
  23. ncbi request reprint PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma
    Christopher W Ryan
    Christopher W Ryan, Oregon Health and Science University, Portland, OR Ofer Merimsky, Sackler School of Medicine, Tel Aviv, Israel Mark Agulnik, Northwestern University, Chicago, IL Jean Yves Blay, Centre Leon Berard, Lyon Antoine Italiano, Institut Bergonie, Bordeaux, France Scott M Schuetze, University of Michigan, Ann Arbor, MI Brian A Van Tine, Washington University in St Louis, St Louis, MO Robin L Jones and Ian R Judson, The Royal Marsden Hospital, London, United Kingdom Anthony D Elias, University of Colorado Denver, Aurora, CO Edwin Choy, Massachusetts General Hospital Jill Y Buck and Francois Lebel, ZIOPHARM Oncology, Boston, MA Thierry Alcindor, McGill University Health Center, Montreal, Quebec, Canada Vicki L Keedy, Vanderbilt University Medical Center, Nashville, TN Damon R Reed, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL Robert N Taub, Columbia University Medical Center Jonathan J Lewis, New York 10032
    J Clin Oncol . 2016
    ..The PICASSO III trial compared doxorubicin plus palifosfamide with doxorubicin plus placebo in patients who had received no prior systemic therapy for metastatic soft tissue sarcoma...
  24. pmc Whole-Field Sequential Intensity-Modulated Radiotherapy for Local-Regional Advanced Head-and-Neck Squamous Cell Carcinoma
    Tamer Refaat
    Departments of Radiation Oncology Medicine, Division of Hematology Oncology Otolaryngology, Head and Neck Surgery Preventive Medicine, Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL Department of Clinical Oncology, Alexandria University, Alexandria, Egypt
    Am J Clin Oncol 38:588-94. 2015
    ..We report the treatment outcomes, adverse events (AEs), and dosimetric parameters in local-regional advanced (LRA) HNSCC patients treated with the WF S-IMRT technique...
  25. pmc Effect of induction chemotherapy on swallow physiology and saliva production in patients with head and neck cancer: a pilot study
    Bharat B Mittal
    Department of Radiation Oncology, Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois
    Head Neck 37:567-72. 2015
    ..No objective data are available to assess the potential damage induction chemotherapy alone contributes to swallowing physiology and salivary production in patients with locally and regionally confined head and neck cancer...
  26. ncbi request reprint Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma
    Christine Elser
    Princess Margaret Hospital, University Health Network, Department of Medical Oncology and Hematology, Toronto, Ontario, Canada
    J Clin Oncol 25:3766-73. 2007
    ..To determine the efficacy and safety of single-agent sorafenib in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) and nasopharyngeal carcinoma (NPC)...
  27. ncbi request reprint Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib
    Mark Agulnik
    Princess Margaret Hospital Phase II Consortium, Toronto, Ontario, Canada
    J Clin Oncol 25:2184-90. 2007
    ..Additional biomarker studies with larger sample sizes are required to elucidate HNSCC patients who may benefit from this targeted therapy...
  28. ncbi request reprint Multidisciplinary Symposium on Head and Neck Cancer. 2 December 2005, Philadelphia, PA, USA
    Mark Agulnik
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, Toronto, Ontario, M5G 2M9, Canada
    Expert Opin Pharmacother 7:489-94. 2006
    ..The management of squamous cell carcinoma of the head and neck has evolved considerably, and with the advent of newer chemotherapeutic agents and molecularly targeted therapies, this field will continue to expand over time...
  29. ncbi request reprint Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents
    Mark Agulnik
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada
    J Clin Oncol 24:4801-7. 2006
    ..To assess the impact and perceptions of patients, physicians, and institutional review board members (IRBs) on the issue of mandatory serial tumor biopsies to acquire tissues for correlative studies...